BOC International: BeiGene (06160) price target raised to HK$276 to maintain “buy” rating

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that BOC International released a research report stating that it raised the target price of BeiGene Shenzhou (06160) from HK$229.2 to HK$276 to maintain the “buy” rating. Driven by factors such as expanded indications, deepening penetration of new patients, and increased compliance and DoT, BeiGene's second-season zebutinib once again achieved sales results that exceeded expectations. At the same time, it also opened up an overseas dosage channel for Ralizubu. In the future, combined use with HER2 will open up 1L HER2+ gastric cancer treatment opportunities. The bank raised the company's 2026-2028 net profit forecast to US$1,026 million, US$1.5 billion and US$2.08 billion, respectively, to reflect the second quarter's performance that exceeded expectations and the latest guidance.